

13th November 2024

- | | |
|---|--|
| <p>(1) BSE Limited
Listing Department,
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai 400 001</p> <p>Scrip Code: 500087</p> | <p>(2) National Stock Exchange of India Limited
Listing Department
Exchange Plaza, 5th floor,
Plot no. C/1, G Block,
Bandra Kurla Complex,
Bandra (East), Mumbai - 400 051</p> <p>Scrip Code: CIPLA EQ</p> |
| <p>(3) SOCIETE DE LA BOURSE DE LUXEMBOURG
Societe Anonyme
35A Boulevard Joseph II,
L-1840 Luxembourg</p> | |

Dear Sir/Madam,

Sub: USFDA inspection at Company's manufacturing facility in Virgonagar, Bengaluru, India

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 we hereby notify that United States Food and Drugs Administration ('USFDA') has conducted an inspection at the Company's manufacturing facility in Virgonagar, Bengaluru from 7th - 13th November 2024.

On conclusion of the inspection, the Company received 8 (eight) observations in Form 483. The Company will work closely with the USFDA and remains committed to address these observations comprehensively within stipulated time.

Please take the above information on record.

Yours faithfully,
For Cipla Limited

Rajendra Chopra
Company Secretary

Prepared by: Mandar Kurghode